GSK (GlaxoSmithKline) this week announced a major new addition to its Hamilton production site. In a GSK news release, the company said a $100 million expansion will provide long-term vaccine manufacturing and more jobs in the Bitterroot Valley facility. The site, on the northeast edge of Hamilton, currently manufactures components of GSK's adjuvant technologies for vaccines. It is one of nine U.S. manufacturing sites. Globally, GSK has 86 sites, producing a variety of medicines, vaccines and other consumer healthcare items. Ravalli County plans include hiring for construction and contracting over the next few years and new permanent employment of scientists, engineers and manufacturing and quality control positions.

Jack Bailey, President of US Pharmaceuticals, said in the news release, "For more than a decade, our Hamilton facility has supported GSK's adjuvant system development program. By expanding the adjuvant system production capabilities in Hamilton, we will continue to deliver long-term and sustainable supply for key vaccines, including SHINGIX." He also thanked Montana Governor Steve Bullock and US Congressmen Jon Tester, Steve Daines and Greg Gianforte for their support. "Montana is emerging as a hub for the biotechnology industry. GSK is grateful for their leadership and the opportunity they have given us to create new jobs and expand our footprint in the state."